Core Insights - Sabra Health Care REIT, Inc. will participate in multiple upcoming conferences, including the 2026 NIC Spring Conference, Deutsche Bank's 2026 Healthcare REIT Summit, and Citi's 2026 Global Property CEO Conference [1][5][6] Company Overview - Sabra Health Care REIT, Inc. operates as a self-administered, self-managed real estate investment trust (REIT) focused on the healthcare industry in the United States and Canada [2] Financial Performance - For the fourth quarter of 2025, Sabra reported a net income of $0.11 per diluted common share, with Funds From Operations (FFO) and Normalized FFO both at $0.36, and Adjusted Funds From Operations (AFFO) at $0.37, with Normalized AFFO at $0.38 [7]

Core Insights - Engineers Gate Manager LP sold 1,513,777 shares of Sabra Health Care REIT, resulting in an estimated transaction value of $28.06 million based on quarterly average pricing [1][7] - The quarter-end value of the stake decreased by $26.85 million, reflecting both the share sale and market price changes [2][7] - Post-transaction, Sabra Health Care REIT accounted for 1.02% of Engineers Gate Manager LP's 13F assets under management, placing it outside the fund's top five holdings [3][7] Company Overview - Sabra Health Care REIT, Inc. is a prominent real estate investment trust specializing in healthcare facilities, with a portfolio of over 400 properties and more than 41,000 beds/units [5][9] - The company generates revenue primarily through leasing properties to healthcare operators and property management agreements, as well as investments in loans receivable and preferred equity [6] Financial Metrics - As of the last twelve months (TTM), Sabra Health Care REIT reported revenue of $774.63 million and net income of $155.61 million [4] - The dividend yield for Sabra Health Care REIT stands at 5.87% [4] - The share price as of market close on February 13, 2026, was $20.17 [4]

Core Insights - Welltower Inc. is a leading healthcare real estate investment trust (REIT) with a market cap of $146.6 billion, focusing on properties serving the healthcare industry in the U.S., Canada, and the U.K. [1] - The company benefits from long-term demographic trends, including aging populations and increasing demand for healthcare services, by partnering with top healthcare systems and operators [2] Company Performance - Welltower's stock reached a 52-week high of $216.43 on February 17 and is currently trading 3.9% below that peak, with shares having increased by 3% over the past three months [3] - Over the past six months, Welltower's stock has risen by 24.2% and by 32.6% over the past 52 weeks, significantly outperforming the Real Estate Select Sector SPDR Fund (XLRE), which saw a 5.4% increase during the same period [4] - The stock has consistently traded above its 200-day moving average over the past year, indicating a bullish trend [4] Financial Highlights - In Q4 FY2025, Welltower reported revenue of approximately $3.18 billion and normalized funds from operations of $1.45 per share, showing strong year-over-year growth [5] - The company's same-store revenue in its senior housing operating portfolio increased by 9.6%, with occupancy rising by about 400 basis points [5] - Welltower completed $13.9 billion in investments and $7.5 billion in dispositions and loan repayments during the quarter, reflecting active portfolio repositioning [5]

Financial Data and Key Metrics Changes - The company reported normalized funds from operation (FFO) of $0.46 per diluted share for Q4 2025 and $1.72 per diluted share for the full year, representing a 22% year-over-year growth in FFO per share compared to 2024 [22][23] - Total portfolio same-store NOI growth was 11.8% in Q4 and 14.2% for the full year 2025, marking the second consecutive year of double-digit growth [10][22] - The debt to EBITDA improved by nearly a full turn in 2025, indicating a stronger financial position [22][25] Business Line Data and Key Metrics Changes - The operating portfolio, including Trilogy and SHOP segments, contributed 76.9% of consolidated cash NOI, with Trilogy's same-store NOI increasing by 14% in Q4 and 18.4% for the full year [11][12] - SHOP segment same-store NOI increased by 24.6% in Q4 and 25.2% for the full year compared to the previous year [13] - Occupancy rates for Trilogy reached 90.6% in Q4, up 275 basis points year-over-year, while SHOP also surpassed 90% occupancy [12][13] Market Data and Key Metrics Changes - The company closed over $950 million in new investments in 2025, primarily in the SHOP segment, which is now the second-largest in terms of cash NOI [16][17] - The investment pipeline remains robust with over $230 million in awarded deals, indicating strong market activity [19][60] Company Strategy and Development Direction - The company maintains a disciplined investment strategy focused on high-quality care and superior health outcomes, with no changes in capital allocation or risk management frameworks [8][21] - The emphasis on high-quality care is expected to drive demand as the aging population grows, positioning the company well for future growth [12][18] - The company is actively pursuing development projects primarily focused on Trilogy expansions, aiming for attractive yields with limited market risk [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another year of double-digit same-store NOI growth in 2026, supported by strong occupancy levels and pricing discipline [12][13] - The leadership transition is described as seamless, with no changes in strategy, ensuring continuity in operations and execution [6][8] - The company anticipates that the demand for high-quality care will continue to grow, providing a favorable environment for its operations [12][18] Other Important Information - The company has been actively involved in off-market acquisitions, leveraging strong relationships with operators to secure favorable deals [82] - The revenue management system is being piloted with various operators, aiming to enhance pricing strategies and improve overall performance [50][51] Q&A Session Summary Question: Can you dive deeper into the acquisition environment? - The company continues to focus on higher acuity SHOP assets, which provide long-term stability [29][30] Question: Can you provide guidance on SHOP's performance? - The company expects a significant increase in pricing power as occupancy rates rise, with a conviction in future growth [35][36] Question: What are the expectations for Trilogy's occupancy and quality mix? - Trilogy's model allows for various drivers of NOI growth, with a focus on shifting to higher payor sources [39][40] Question: How is the revenue management system being rolled out? - The revenue management system is being tested with select operators, aiming to enhance their performance [50][51] Question: What is the status of the investment pipeline? - The pipeline is dynamic, with a high level of deal activity and a focus on off-market opportunities [60][61]

Financial Data and Key Metrics Changes - The company reported normalized funds from operation (NFFO) of $0.46 per diluted share for Q4 2025 and $1.72 per diluted share for the full year, representing a 22% year-over-year growth in NFFO per share [22][23] - Total portfolio same-store NOI growth was 11.8% in Q4 and 14.2% for the full year 2025, marking the second consecutive year of double-digit growth [10][22] - The debt to EBITDA improved by nearly a full turn in 2025, with a net debt to EBITDA ratio of 3.4x [22][25] Business Line Data and Key Metrics Changes - The operating portfolio, including Trilogy and SHOP segments, contributed 76.9% of consolidated cash NOI, with Trilogy's same-store NOI increasing by 14% in Q4 and 18.4% for the full year [11][12] - SHOP segment same-store NOI increased by 24.6% in Q4 and 25.2% for the full year 2025, with occupancy surpassing 90% [13][14] - Trilogy's occupancy reached 90.6% in Q4, up 275 basis points year-over-year, supported by improved quality mix and Medicare penetration [12][13] Market Data and Key Metrics Changes - The company closed over $950 million in new investments in 2025, primarily in the SHOP segment, which is now the second-largest in terms of cash NOI [16][17] - The investment pipeline remains robust, with over $230 million in awarded deals and continued deal activity expected in 2026 [19][60] Company Strategy and Development Direction - The company maintains a disciplined healthcare investment strategy focused on high-quality care and superior health outcomes, with no changes in capital allocation or risk management frameworks [8][21] - The company is prioritizing expansions in Trilogy and campus growth initiatives, aiming for attractive incremental yields with limited market risk [21] - The focus remains on relationship-driven sourcing and disciplined underwriting to ensure long-term cash flow durability and growth [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering another year of double-digit same-store NOI growth in 2026, supported by strong occupancy levels and pricing tailwinds [12][13] - The company anticipates continued demand for high-quality operators in the aging population sector, with expectations of sustained growth in the coming years [12][18] - Management highlighted the importance of maintaining operational momentum and capital availability to capitalize on growth opportunities [25][26] Other Important Information - The company has successfully accelerated several previously announced pipeline deals, closing approximately $665 million in new acquisitions in Q4 2025 [19] - The management team emphasized the importance of high-quality care and outcomes, which have contributed to strong financial performance [15][18] Q&A Session Summary Question: Can you dive deeper into the acquisition environment? - Management noted a focus on higher acuity SHOP assets, indicating confidence in long-term stability in that asset class [29] Question: Can you provide insights on SHOP guidance and occupancy? - Management acknowledged a significant occupancy increase in SHOP but indicated that future growth may not match previous years' rates [35] Question: What is the outlook for Trilogy's occupancy and quality mix? - Management highlighted the unique model of Trilogy and the importance of shifting to higher payor sources to drive NOI growth [39] Question: How does the revenue management system rollout progress? - Management confirmed that the revenue management system is being piloted with select operators, aiming to enhance overall portfolio performance [50] Question: What is the status of the investment pipeline and expected yields? - Management indicated that current acquisitions are stabilizing in the high 5% to low 6% range, with a focus on higher quality properties [67]

Financial Data and Key Metrics Changes - The company reported normalized FFO per share of $1.61 for the full year 2025, exceeding the midpoint of original guidance by $0.03 [9] - Same-store NOI growth was 4.8%, surpassing the midpoint of original guidance by 140 basis points [10] - In Q4 2025, normalized FFO per share was $0.40, with same-store cash NOI growth of 5.5% [22] Business Line Data and Key Metrics Changes - The company executed approximately 5.8 million sq ft of leases in 2025, including 1.6 million sq ft of new leases [13] - Tenant retention improved to 82% for the year, with same-store absorption translating to over 100 basis points of occupancy gain [13][14] - Cash leasing spreads improved by 60 basis points, and tenant retention increased by 220 basis points under the new asset management platform [6] Market Data and Key Metrics Changes - The company exited 14 non-core markets, improving its geographic footprint into high-growth MSAs [7] - Demand in the top 100 MSAs continues to outstrip supply, with completions as a percentage of inventory remaining near all-time lows [15] Company Strategy and Development Direction - The company aims to become the clear leader in the outpatient medical sector, focusing on long-term shareholder value [4] - A three-year strategic plan was published in July, with key steps to overhaul the organization, including a revamp of the asset management platform and a successful asset disposition plan [5][6] - The company plans to prioritize redevelopment projects within its existing portfolio, targeting attractive yields on cost of approximately 10% [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's premier outpatient medical portfolio, supported by nearly 5% same-store NOI growth in 2025 [7] - The outlook for 2026 includes normalized FFO per share guidance of $1.58-$1.64, with same-store cash NOI growth expected to be between 3.5%-4.5% [24] - Management acknowledged the need for disciplined capital allocation due to current cost of capital and discount to intrinsic asset value [10] Other Important Information - The company successfully achieved a target of $10 million run rate G&A savings, with total G&A expenses now at $45 million [6] - The dividend was right-sized, offering a nearly 6% current yield to shareholders [9] Q&A Session Summary Question: Same-store NOI guidance for 2026 - Management explained that the 3.5%-4.5% guidance reflects expectations for escalators, retention, absorption, and cash leasing spreads, with a focus on pushing these metrics [30][31] Question: CapEx relative to FAD for 2026 - Management indicated that if FFO is flat, FAD is also expected to be flat, with maintenance capital numbers provided in guidance [36][38] Question: Absorption potential and redevelopment leasing - Management confirmed that the absorption figures discussed were for the same-store pool, with expectations for redevelopment projects to drive total portfolio occupancy increases [40][42] Question: Acquisition potential and profile - Management stated that any acquisitions would be pursued only if they meet yield expectations, emphasizing discipline in capital allocation [44][46] Question: Disposition plans going forward - Management outlined that $175 million of sales are embedded in guidance for the year, with some sales expected to close early in 2026 [48] Question: Changes in office repositionings and shadow supply - Management noted no significant changes in shadow supply affecting their markets, focusing on health system leasing [78] Question: Balance sheet and debt mix - Management indicated a target of mid-single digits to upper single digits for floating rate debt, emphasizing balance sheet efficiency [80]

Group 1 - The company has announced a series of ordinary dividends totaling $1.2000000 per share for the year 2025, with a consistent distribution of $0.3000000 per share across four payment dates [1][2] - The breakdown of the dividends includes qualified dividends of $0.9755384 per share and non-qualified dividends of $0.2244616 per share, indicating a clear distinction in the types of dividends being distributed [2] - The payment dates for the dividends are set for February 28, May 30, August 29, and November 28 in 2025, ensuring regular cash flow for shareholders throughout the year [1][2] Group 2 - The total ordinary dividends for the year represent a distribution rate of 100.00%, with qualified dividends making up 81.29% and non-qualified dividends accounting for 18.71% of the total [2] - The company has maintained a consistent dividend policy, reflecting its commitment to returning value to shareholders while managing its earnings effectively [1][2]

Core Insights - Ventas, Inc. (VTR) is a healthcare REIT with a market cap of $36.1 billion, focusing on senior housing, medical office buildings, life science facilities, and healthcare-related properties [1] - The company is expected to announce its fiscal Q4 earnings for 2025 soon, with analysts predicting a profit of $0.89 per share, a 9.9% increase from the previous year [2] - Ventas has consistently exceeded Wall Street's bottom-line estimates for the last four quarters, with a forecasted FFO of $3.48 per share for the current fiscal year, representing a 9.1% increase from fiscal 2024 [3] Financial Performance - In Q3, Ventas reported total revenue of $1.5 billion, a 20.4% year-over-year increase, surpassing consensus estimates by 4.2% [5] - The company's normalized FFO for Q3 was $0.88, which improved 10% from the same quarter last year, exceeding analyst expectations [5] - The strong performance was attributed to the senior housing operating portfolio (SHOP), which saw double-digit organic growth year-over-year [5] Market Performance - Over the past 52 weeks, Ventas shares have increased by 32.6%, outperforming the S&P 500 Index's 19.3% return and the State Street Real Estate Select Sector SPDR ETF's 2.3% increase [4] - Wall Street analysts have a highly optimistic outlook for VTR, with a "Strong Buy" rating from 16 out of 21 analysts, and a mean price target of $86.40, indicating a 12.3% potential upside [6]

Core Viewpoint - Healthpeak Properties, Inc. has received a downgrade from Jefferies, indicating a cautious outlook on the stock despite some mixed investor sentiment [2][6]. Company Overview - Healthpeak Properties, Inc. is a real estate investment trust (REIT) focused on the healthcare real estate sector, involved in the acquisition, development, and management of healthcare properties across the United States [1]. Stock Performance - The stock was downgraded from a Buy to a Hold by Jefferies, with a current price of $16.66, although it saw a slight increase of approximately 0.24% or $0.04 during the trading session [2]. - The stock has experienced significant volatility over the past year, with a high of $21.28 and a low of $16.44, amidst a market capitalization of approximately $11.58 billion [5][6]. Investor Sentiment - Cullen Capital Management LLC has reduced its investment in Healthpeak Properties by 5%, now holding 9.59 million shares, which constitutes about 1.9% of its portfolio, reflecting a conservative stance [3][6]. - Conversely, Brooklyn Investment Group has increased its stake by 198.9% in the first quarter, now holding 1,312 shares valued at $27,000, indicating a bullish perspective [4][6].

Core Insights - Medical Properties Trust (MPW) shares have increased by 27.8% over the past three months, significantly outperforming the industry growth of 0.1% [1][7] - The company is a healthcare real estate investment trust (REIT) focused on acquiring and developing net-leased healthcare facilities, including hospitals and urgent care facilities [1] Market Dynamics - The senior citizens' population is projected to rise, leading to increased national healthcare expenditures, particularly from this demographic, which is a major customer base for healthcare services [2] - The healthcare sector is relatively insulated from macroeconomic challenges faced by other sectors, providing stability amid market volatility as consumers prioritize healthcare spending over discretionary purchases [3] Business Model and Financials - Medical Properties leases facilities to healthcare operating companies with initial lease terms of at least 15 years, most including five-year renewal options, and over 99% of leases have annual rent escalations linked to the Consumer Price Index [4] - The company aims to generate over $1 billion in total annualized cash rent by the end of 2026 [4] - Strategic sell-outs have provided the company with capital for reinvestment; in the first nine months of 2025, it sold five facilities for approximately $100 million, resulting in a gain of nearly $4 million [5] Financial Strength - As of November 4, 2025, Medical Properties had about $1.1 billion in liquidity, with no debt maturities due in 2025 following refinancing transactions in February 2025 [8] - The company’s access to diverse capital sources through capital recycling and internal cash flow enhances its financial flexibility, supporting growth initiatives [8] Future Outlook - Given the aforementioned factors, the positive trend in MPW's stock price is expected to continue in the near term [9]